Extended data table 1. Baseline Participant Characteristics.
Parameters | Placebo (n = 11) | Pasteurized (n=12) | Alive (n = 9) | Ptotal | P1 | P2 |
---|---|---|---|---|---|---|
Age (years) | 49,45 ± 9,67 | 52,75 ± 7,16 | 52,89 ± 8,59 | 0,58a | 0,36 | 0,42 |
Sex (nb (%)) | ||||||
Male | 5 (45) | 4 (33) | 6 (67) | |||
Female | 6 (55) | 8 (67) | 3 (33) | |||
Height (cm) | 173,05 ± 9,32 | 170,54 ± 8,8 | 172,11 ± 10,15 | 0,81a | 0,52 | 0,83 |
Body Weight (kg) | 112,45 ± 16,74 | 115,91 ± 17,23 | 109,03 ± 13,96 | 0,63a | 0,63 | 0,63 |
BMI | 37,63 ± 5,82 | 39,81 ± 4,77 | 36,82 ± 3,68 | 0,35a | 0,34 | 0,72 |
Waist (cm) | 120,2 ± 12,51 | 126,46 ± 8,75 | 120,06 ± 10,43 | 0,29a | 0,19 | 0,97 |
Hip (cm) | 118,8 (12,4) | 123,46 (7,8) | 117,83 (16,5) | 0,22b | 0,13 | 0,65 |
Waist-hip ratio | 1,02 ± 0,11 | 1,03 ± 0,09 | 1,02 ± 0,10 | 0,97a | 0,82 | 0,94 |
Systolic blood pressure (mm Hg) | 150 (12) | 150,00 (20) | 140,00 (19) | 0,15b | 0,38 | 0,18 |
Diastolic blood pressure (mm Hg) | 90,00 (9) | 102,50 (19) | 100 (19) | 0,08b | 0,02 | 0,44 |
Fasting Blood glucose (mg/dl) | 100,33 (11,67) | 103,00 (15,08) | 94,33 (18,5) | 0,34b | 0,24 | 0,82 |
Glycated hemoglobin A1c (%) | 5,53 ± 0,36 | 5,77 ± 0,42 | 5,63 ± 0,35 | 0,33a | 0,11 | 0,52 |
Insulinemia (pmol/L) | 111,36 (28,83) | 155,83 (57,01) | 128,7 (86,42) | 0,030b * | 0,014 * | 0,47 |
% insulin sensibility | 34,00 (8,5) | 23,75 (9,17) | 30,8 (21,65) | 0,025b * | 0,007 * | 0,5 |
Total Cholesterol (mg/dl) | 200,73 ± 43,19 | 203,00 ± 51,34 | 198,67 ± 20,47 | 0,97a | 0,91 | 0,9 |
LDL Cholesterol (mg/dl) | 131,63 ± 37,64 | 129,92 ± 41,10 | 128,78 ± 18,63 | 0,98a | 0,92 | 0,84 |
HDL Cholesterol (mg/dl) | 42 (7) | 44,5 (12,25) | 43 (18,5) | 0,70b | 0,41 | 0,82 |
Ratio (tot cholesterol/HDL) | 4,65 ± 1,05 | 4,59 ± 1,14 | 4,84 ± 0,92 | 0,86a | 0,91 | 0,61 |
Aspartate aminotransferase activity (U/L) | 17,00 (8) | 23 (17,75) | 20 (11,5) | 0,26b | 0,12 | 0,49 |
Alanine aminotransferase activity (U/L) | 21 (14) | 37,5 (26,25) | 30,78 (28,5) | 0,14b | 0,42 | 0,34 |
ɣ-Glutamyltransferase activity (U/L) | 21 (17) | 40,5 (51) | 27 (5) | 0,084b | 0,45 | 0,13 |
Lactate dehydrogenase activity (UI/L) | 166 (21) | 197,5 (41,75) | 180 (50) | 0,082b | 0,023 | 0,46 |
Creatine kinase (U/L) | 90 (64) | 96 (100) | 111 (48,50) | 0,68b | 0,48 | 0,33 |
Triglycerides (mg/dl) | 127,45 ± 46,49 | 139,83 ± 47,79 | 135,56 ± 44,13 | 0,84a | 0,58 | 0,69 |
DDPIV activity (mU/ml) | 14,72 (4,45) | 15,58 (7,67) | 13,89 (3,13) | 0,12b | 0,36 | 0,18 |
ptotal: aP-values from one-way ANOVA except for Sex; bP-values from Kruskal-Wallis.
P1-2 = P-values for comparison of Placebo groups versus Pasteurized group (P1) and versus Alive group (P2) with the two-tailed Mann-Whitney U test or two-tailed unpaired T-test according to the distribution, with p > 0,017 due to the Bonferroni adjustment. Baseline values are presented as mean + SD for normal variables while non-normal variables are presented as Median (inter-quartile range).
Significant difference between groups value (P < 0.05 for Ptotal ; P < 0.017 for P1 & P2)